Department of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Int J Stroke. 2023 Jun;18(5):620-625. doi: 10.1177/17474930221122681. Epub 2022 Sep 7.
Tirofiban is a glycoprotein IIb/IIIa receptor inhibitor that has been shown to be effective in the treatment of acute coronary syndromes. However, it remains unknown whether it improves outcomes in patients with acute ischemic stroke.
This trial investigates the efficacy and safety of tirofiban compared with aspirin for acute ischemic stroke within 24 h after symptom onset.
The Efficacy and Safety of Tirofiban Compared with Aspirin in the Treatment of Acute Ischemic Stroke (RESCUE BT 2) Trial is an investigator-initiated, prospective, randomized, double-blind, double-dummy, multicenter clinical trial. Up to 1158 eligible patients will be consecutively randomized to receive antiplatelet therapy with tirofiban or aspirin in 1:1 ratio across approximately 100 stroke centers in China.
The primary endpoint is the proportion of patients with excellent functional outcomes defined as a modified Rankin scale score of 0 to 1 at 90 days after randomization. Lead safety endpoints include mortality at 90 days and symptomatic intracerebral hemorrhage within 48 h after treatment.
ChiCTR2000029502 (www.chictr.org.cn).
替罗非班是一种糖蛋白 IIb/IIIa 受体抑制剂，已被证明在治疗急性冠脉综合征方面有效。然而，它是否能改善急性缺血性脑卒中患者的结局仍不清楚。
本试验旨在研究替罗非班与阿司匹林在急性缺血性脑卒中发病后 24 小时内的疗效和安全性。
替罗非班与阿司匹林治疗急性缺血性脑卒中的疗效和安全性（RESCUE BT 2）试验是一项由研究者发起的、前瞻性、随机、双盲、双模拟、多中心临床试验。将连续入选的约 1158 例符合条件的患者按 1:1 的比例随机分配至替罗非班组或阿司匹林组接受抗血小板治疗，试验将在中国约 100 家卒中中心进行。
主要终点是 90 天时改良 Rankin 量表评分 0-1 分的患者比例，定义为良好功能结局。主要安全性终点包括 90 天时的死亡率和治疗后 48 小时内的症状性颅内出血。
ChiCTR2000029502（www.chictr.org.cn）。
